Implementation Guide: Integrated Medications for Addiction Treatment (MAT) for Opioid Use Disorder (OUD) in a Serious Mental Illness (SMI) Service Setting

This resource was created by SMI Adviser content partners and approved by the SMI Adviser clinical expert team for inclusion in the knowledge base.

This implementation guide is designed to provide guidance to administrative, clinical and/or medical leaders of organizations and programs serving people with serious mental illness (SMI) on how to implement integrated medication for addiction treatment (MAT) services for current clients who have co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD). Medication for AUD (naltrexone and acamprosate) will be discussed as a component of implementation of medication (buprenorphine and naltrexone) for OUD.

Organizations serving people with SMI are variable in size and scope. This guide describes an implementation process for a “mid-sized” organization with several programs and sites and with a small cohort of prescribers (psychiatrists, advanced practice nurses) covering those sites. The content of the guide can be adapted for smaller and larger organizations.

ACCESS RESOURCE

See additional implementation guides on SMI and SUD:

• Serious Mental Illness (SMI) and Co-Occurring Disorders (COD)
• Integrated screening and longitudinal, strength-based assessment for individuals with serious mental illness (SMI) and co-occurring substance use
• Stage-Matched Interventions for Individuals with Serious Mental Illness (SMI) and Co-Occurring Substance Use
• Skill-Building Interventions for Individuals with Serious Mental Illness (SMI) and Co-Occurring Substance Use Disorders